Cited by 104Treatment of Major DepressionTranscranial Magnetic Stimulation StudiesNeurotransmitter Receptor Influence on Behavior

Ketamine normalizes subgenual cingulate cortex hyper-activity in depression

Open access
Morris, Laurel S., Costi, Sara, Tan, Aaron, Stern, Emily R., Charney, Dennis S., Murrough, James W.·2020·Neuropsychopharmacology

Abstract

Mounting evidence supports the rapid antidepressant efficacy of the N-methyl-D-aspartate receptor antagonist, ketamine, for treating major depressive disorder (MDD); however, its neural mechanism of action remains poorly understood. Subgenual anterior cingulate cortex (sgACC) hyper-activity during rest has been consistently implicated in the pathophysiology of MDD, potentially driven in part by excessive hippocampal gluatmatergic efferents to sgACC. Reduction of sgACC activity has been associated with successful antidepressant treatment. This study aimed to examine whether task-based sgACC activity was higher in patients with MDD compared to controls and to determine whether this activity was altered by single-dose ketamine. In Study 1, patients with MDD (N = 28) and healthy controls (N = 20) completed task-based functional magnetic resonance imaging using an established incentive-processing task. In Study 2, a second cohort of patients with MDD (N = 14) completed the same scanning protocol at baseline and following a 40 min infusion of ketamine (0.5 mg/kg). Task-based activation of sgACC was examined with a seed-driven analysis assessing group differences and changes from pre to post treatment. Patients with MDD showed higher sgACC activation to positive and negative monetary incentives compared to controls, associated with anhedonia and anxiety, respectively. In addition, patients with MDD had higher resting-state functional connectivity between hippocampus and sgACC, associated with sgACC hyper-activation to positive incentives, but not negative incentives. Finally, ketamine reduced sgACC hyper-activation to positive incentives, but not negative incentives. These findings suggest a neural mechanism by which ketamine exerts its antidepressant efficacy, via rapid blunting of aberrant sgACC hyper-reactivity to positive incentives.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/s41386-019-0591-5

Cites

43 of 43 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Ketamine infusion reduced FC between the sgACC and limbic regions (e.g., hippocampus).

    “Specifically, ketamine infusion reduced (1) hyperactivation in the sgACC (BA25) to positive feedback [121], (2) FC between the pgACC and dACC [199], and (3) FC between the sgACC and limbic regions (e.g., hippocampus) [121].”

    From Prefrontal cortex and depression (2022) · cites this paper as [121]

    The Effects of ketamine section explicitly reports no significant change in hippocampus–sgACC connectivity before versus after ketamine (p > 0.05). The Discussion mentions reduced connectivity in a previous study of healthy men, but that is not the finding of this paper’s ketamine cohort. (LLM, conf=0.90)

    Checked by a reasoning model — may be wrong.

    Experimental — accuracy not yet measured
  • Among TRD patients, sgACC hyper-activation to positive feedback correlated with more anticipatory anhedonia (but not anxiety symptoms).

    “Finally, among TRD patients, sgACC hyper-activation to positive feedback correlated with more anticipatory anhedonia (but not anxiety symptoms) [121].”

    From Prefrontal cortex and depression (2022) · cites this paper as [121]

    The Participants results report that sgACC activation to positive feedback correlated with worse anticipatory anhedonia, but not anxiety. However, the correlation was calculated across the full sample of depressed patients and healthy controls, not specifically among TRD patients. The Participants and procedures section does not establish treatment resistance as a criterion for that cohort. (LLM, conf=0.90)

    Experimental — accuracy not yet measured
  • Ketamine infusion reduced hyperactivation in the sgACC (BA25) to positive feedback.

    “Specifically, ketamine infusion reduced (1) hyperactivation in the sgACC (BA25) to positive feedback [121], (2) FC between the pgACC and dACC [199], and (3) FC between the sgACC and limbic regions (e.g., hippocampus) [121].”

    From Prefrontal cortex and depression (2022) · cites this paper as [121]

    The Discussion reports that ketamine reduced sgACC activation to positive feedback in patients with MDD (Fig. 3). However, the BA25-specific analysis in “Subdivisions within sgACC” found only a trend toward reduced hyperactivity (p = 0.062), so the claim states that more specific result more firmly than the paper does. (LLM, conf=0.85)

    Experimental — accuracy not yet measured
  • sgACC hyper-activation to positive (but not negative) incentives was normalized (decreased) by a single ketamine infusion.

    “Importantly, sgACC hyper-activation to positive (but not negative) incentives was normalized (decreased) by a single ketamine infusion.”

    From Prefrontal cortex and depression (2022) · cites this paper as [121]

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Research works printed but not linked: 1

  1. [28]28. Jenkinson M, Beckmann CF, Behrens TE, Woolrich MW, Smith SM. Fsl. Neuro- image. 2012;62:782-90.

Cited by

Sorted by citations

Authors
Morris, L. S., Costi, S., Tan, A., Stern, E. R., Charney, D. S., & Murrough, J. W.
Affiliations
  • Icahn School of Medicine at Mount Sinai (US)
  • New York University (US)
Corresponding author
Murrough, James W.
Venue
Neuropsychopharmacology
Published
2020-01-02
Volume
45
Issue
6
Pages
975-981
ISSN
  • 0893-133X (ISSN-L)
  • 1740-634X
OpenAlex
W2997603839
Cited by
104
References
43
Citations by year
2026: 10 · 2025: 12 · 2024: 18 · 2023: 17 · 2022: 13 · 2021: 24 · 2020: 10
FWCI
9.60
Type
journal article
Language
en
Open access
Locations
  • Neuropsychopharmacology (publishedVersion)
  • PubMed Central (publishedVersion)
  • PubMed (publishedVersion)
Funders
National Institute of Mental Health (L30 MH095136, R21MH109771, K23MH094707)
Topics
  • Health Sciences › Medicine › Pharmacology › Treatment of Major Depression
  • Life Sciences › Neuroscience › Neurology › Transcranial Magnetic Stimulation Studies
  • Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neurotransmitter Receptor Influence on Behavior
Keywords
ketamine, major depressive disorder, subgenual anterior cingulate cortex, antidepressant mechanism, NMDA receptor antagonists, anhedonia, anxiety, resting-state functional connectivity
MeSH terms
Depression, Major Depressive Disorder, Gyrus Cinguli, Humans, Ketamine, Magnetic Resonance Imaging

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review